STAAR SURGICAL CO (STAA) Stock
STAA has an Alpha Score of 39 out of 100 (weak), computed on Nov 9, 2026 from 3 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported STAA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Point72's at $69.93M. Its trailing P/E ratio is 329.3 and its net margin 1.1% (key statistics as of Nov 9, 2026).
What is STAA's Alpha Score?
How it works →Alpha Score of 39 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own STAA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Point72 Steve Cohen | 2.44M | $69.93M | +196% |
| Renaissance Technologies Jim Simons (founder) | 340K | $9.77M | +152% |
| Citadel Ken Griffin | 233K | $6.70M | -78% |
| D.E. Shaw David Shaw | 22K | $631.3K | -21% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are STAA's key statistics?
Key statistics as of Nov 9, 2026
How does STAA's valuation compare with the Healthcare sector?
| Metric | STAA | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 329.3 | 28.8 | 113 |
| Net margin | 1.13% | 3.66% | 170 |
| Return on equity | 1.08% | 3.71% | 194 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
STAA price chart
Powered by TradingViewWhat does STAAR SURGICAL CO do?
Staar Surgical Company designs, develops, manufactures, and sells implantable lenses for eye surgery, operating primarily in the ophthalmic medical devices sector. The company offers two main product categories: Implantable Collamer lenses (ICL) used in refractive surgery to correct vision problems without removing the eye's natural lens, and intraocular lenses (IOL) used in cataract surgery. Staar Surgical delivers these products through specialized accessory delivery systems designed for surgical use. With over 2.5 million implants performed worldwide, the company serves ophthalmic surgeons and surgical centers globally. The ophthalmic surgical product segment generates the majority of Staar Surgical's revenue. Founded in 1982 and headquartered in Lake Forest, California, Staar Surgical operates as a medical device manufacturer focused on vision correction and cataract treatment solutions for healthcare providers and patients seeking surgical vision correction alternatives.